Videos
-
Audience Q&A
3/8/2023
During each Cell & Gene Live, our audience can submit real-time questions for our expert panelists. Watch and listen as Michael Blackton and John Lee provide detailed, insightful responses to our audience questions on everything from how changing from a lab-based adherent protocol to suspension scalable protocol improved the cell product to whether a container with lesser cells, identical cell density, and composition be used for establishing stability for cell therapy products, and much more.
-
Design And Execution Of Comparability Studies
3/8/2023
During Cell & Gene Live, "Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing," Michael Blackton and John Lee provided detail on how successful comparability studies are designed and executed. They covered the in-process and release testing requirements, as well as the common and uncommon pit falls that have been encountered.
-
Donor-To-Donor Variability
3/8/2023
For cell-based products, donor-to-donor variability is the primary source of complexity associated with establishing product comparability. In this segment of Cell & Gene Live, "Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing," Michael Blackton and John Lee cover why donor-to-donor variability is an on-going challenge and potential solutions.
-
How The Process Influences The Product
3/8/2023
Here, during this segment of Cell & Gene Live, "Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing," Michael Blackton and John Lee highlight the various ways to demonstrate our understanding of how the process influences the product, as well as how the product’s structure influences its clinical function.
-
Increased Comparability Burden During Clinical Trials
3/8/2023
As a therapy proceeds through Phases I / II and into Phase III clinical trials, the comparability burden increases. As the body of knowledge increases, the comparability burden evolves. Some tests may be removed while others are added, and assumptions may change with data. In this segment of Cell & Gene Live, "Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing," Michael Blackton and John Lee break down the comparability requirements from early- to late-stage programs.
-
Challenges Associated With Comparability For Cell-Based Products
3/8/2023
During this Cell & Gene Live, "Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing," Cell & Gene's Chief Editor, Erin Harris, Michael Blackton, former SVP Cell Therapy Manufacturing at Nurix Therapeutics, and John Lee, SVP, Head of Cell Therapy at Center for Breakthrough Medicines, talk through the CGT sector's greatest struggles with comparability. Indeed in this segment, Blackton and Lee cover the sector's biggest challenges to date from the need to truly understand the product to precise analytics and eliminating silos, and more.
-
How To Choose Your Tools For 3D Cell Culture
8/19/2022
In this video our application scientists walk you through common research goals and the most suitable 3D cell culture solutions for each.
-
Teach Me In 10: Techniques For Harvesting Adherent Cells
8/19/2022
There are many harvesting options depending on the cell line and application. In this video we discuss some tips and tricks for harvesting cells.
-
Corning® Matribot® Bioprinter: Accelerate Development And Streamline The Workflow Of 3D Models
8/19/2022
The Corning® Matribot® bioprinter uses a revolutionary cooling syringe printhead technology that allows you to dispense 3D droplets or droplet arrays for organoid applications.
-
Do More With Corning® HYPERStack® Cell Culture Vessels
8/19/2022
With gas-permeable film, this closed system offers more surface area within a compact footprint. Watch this short video to learn more.